Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26536401 | 0.95 | TNKS2 (0.37) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536547 | 0.90 | TNKS2 (0.34) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536550 | 0.88 | KIF11 (0.34) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536393 | 0.85 | TNKS (0.37) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536387 | 0.76 | KIF11 (0.41) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536433 | 0.75 | TNKS (0.41) | TNKSTNKS2MEN1HPGDHTT | |
| SCHEMBL26536395 | 0.74 | TNKS (0.33) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536418 | 0.72 | TNKS2 (0.41) | TNKSTNKS2KDM4EMEN1HCRTR1 | |
| SCHEMBL26536423 | 0.71 | BCHE (0.37) | TNKSTNKS2MEN1KMT2ACDK4 | |
| SCHEMBL26536462 | 0.68 | KIF11 (0.41) | TNKSTNKS2KDM4EMEN1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322802-A1 | LIGHT EMITTING DEVICE AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322802-A1 | LIGHT EMITTING DEVICE AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322802-A1 | LIGHT EMITTING DEVICE AND FUSED POLYCYCLIC COMPOUND FOR THE LIGHT EMITTING DEVICE | CRY1, LAGE3, CRY2 | TNKS 1133/4885TNKS2 1405/4885KDM4E 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.